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Background:  Patients  with  activating  somatic  mutations  in the  Epidermal  Growth  Factor  Receptor  (EGFR)
have  better  clinical  outcomes  when  treated  with  Tyrosine  Kinase  Inhibitors  (TKI)  over  chemotherapy.
However,  the  impact  of the  use  of  TKIs  on  overall  survival  outside  clinical  trials  is not  well  established.
Objective:  To  characterize  and  analyze  the overall  survival  of  a Caucasian  population  with  NSCLC  and
EGFR  mutations.
Methods:  A retrospective  cohort  analysis  of patients  with  NSCLC  screened  for  EGFR  mutations  (exons
18–21)  between  October  2009  and July  2013 was  conducted.  Clinical  and  pathological  characteristics,
mutational  EGFR  status,  treatment  and  overall  survival  were  evaluated.
Results:  From  the  285  patients  which  performed  screening  for  EGFR  mutations,  54  (18.9%)  had  mutations,
25  (46.3%)  of  which  in exon  19  and 20 of  which  (37.0%)  in  exon  21. The  occurrence  of mutations  was
associated  with  female  sex  and  non-smoking  habits  (both,  P  <  .001).  The  median  survival  of  the  global
population  was  12.0  months,  with  a better  overall  survival  in mutated  than  non-mutated  patients  (20.0
vs  11.0  months,  respectively;  P  =  .007).
Conclusion: These  data  contribute  for  a better knowledge  of  our  lung  cancer  population  concerning  the
mutational  status  and  clinical  outcomes,  confirming  a  better  overall  survival  for  the patients  with  EGFR
TKI sensible  mutations.
© 2017  SEPAR.  Published  by  Elsevier  España,  S.L.U.  All rights  reserved.
Análisis  de  la  supervivencia  global  y caracterización  del  perfil  mutacional  del
gen  EGFR  en  una  población  con  cáncer  de  pulmón  no  microcítico
alabras clave:
eceptor del factor de crecimiento
r  e  s  u  m  e  n
Antecedentes:  Los  pacientes  con  mutaciones  somáticas  activantes  en  el  receptor  del factor  de  crecimiento
epidérmico  (EGFR)  obtienen  mejor  resultado  clínico  cuando  se tratan  con  inhibidores  de  la  tirosina  cinasapidérmico
nhibidores de tirosina cinasa
upervivencia global en cáncer de pulmón
(TQ) frente  a quimioterapia.  Sin  embargo,  el  impacto  de la  terapia  en  inhibidores  de  TQ  en  la  supervivencia
global  de  los  pacientes  no  está  del todo  establecido  en la  práctica  clínica  habitual.
Objetivo:  Caracterizar  y analizar  la  supervivencia  global  de  una  población  caucásica  con  cáncer  de  pulmónáncer de pulmón no microcíticoPlease cite this article in press as: Aguiar F, et al. Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung
Cancer (NSCLC) Population. Arch Bronconeumol. 2017. http://dx.doi.org/10.1016/j.arbres.2017.07.012
ulmón no microcítico  y mutaciones  en  el  gen  EGFR.
Métodos:  Se  realizó  un  análisis  retrospectivo  de una  cohorte  de  pacientes  con  cáncer  de  pulmón  no
microcítico  con  mutaciones  en  el gen  EGFR  (exones  18-21)  entre  octubre  de  2009  y julio  de  2013.  Se
evaluaron  las  características  clínicas  y  patológicas,  el  estatus  mutacional  del gen  EGFR,  el  tratamiento  y
la supervivencia  global.
Abbreviations: NSCLC, Non-Small Cell Lung Cancer; EGFR, Epidermal Growth Factor Receptor; TKI, Tyrosine Kinase Inhibitors.
∗ Corresponding author.
E-mail address: f.lemos.aguiar@gmail.com (F. Aguiar).
http://dx.doi.org/10.1016/j.arbres.2017.07.012
300-2896/© 2017 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.
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Resultados:  De  los  285  pacientes  que  se cribaron  para  caracterización  de  mutaciones  en  el gen  EGFR,  54
(18,9%)  presentaron  mutaciones,  de  los  cuales  25  (46,3%)  tenían  mutaciones  en el exón  19  y 20  (37,0%)
en el exón  21.  Se observó  que  la  ocurrencia  de  mutaciones  estaba  asociada  al género  femenino  y  al  no
consumo  de  tabaco  (p  <  0,001  en ambos  casos).  La  supervivencia  media  de  la población  global  fue  de  12
meses,  con  una  mejor  supervivencia  global  en  pacientes  que  presentaron  mutaciones  que en  los que  no
las  presentaron  (20  vs. 11 meses,  respectivamente,  p =  0,007).
Conclusión:  Estos  datos  contribuyen  a mejorar  el conocimiento  de  nuestra  población  con  cáncer  de pulmón
con relación  a su  estatus  mutacional  y  el  resultado  clínico,  confirmando  una  mayor  tasa  de  supervivencia












































Lung Cancer is the most frequent cause of cancer death.1
SCLC is more often diagnosed in advanced stages,2 which reduces
he therapeutic options to cytotoxic chemotherapy, with modest
utcomes.3 Its poor prognosis turns this disease into an emergent
rea of investigation.
The Epidermal Growth Factor Receptor (EGFR) belongs to the
rbB family, composed by several transmembrane tyrosine kinase
eceptors.4 These receptors mediate extracellular growth factors
uch as the epidermic growth factor.4 Dysregulation of these recep-
ors leads to uncontrolled proliferation and increased resistance to
poptosis5 as well as modified cell adhesion and increased migra-
ion capacity, facilitating neoplastic invasion and metastization.6
The EGFR tyrosine kinase domain is found in the exons 18–24
nd the more relevant mutations are located in the exons 18–21.7
he most frequent EGFR mutations consist in in-frame deletions
n exon 19, by the modification of the LREA amino-acid motif
delE746–750) and in missense mutations in exon 21 (L858R
odon).8
The presence of EGFR mutations in NSCLC is associated to cer-
ain clinical characteristics as female sex, Asian ancestry, absence
f smoking habits and histology of adenocarcinoma.8
EGFR tyrosine kinase inhibitors (TKI) were first used in a
on-selective way in NSCLC treatment resulting in disappointing
utcomes, being effective only in a small proportion of patients.9
The first evidence that EGFR mutations could be used as a target
herapy emerged thirteen years ago.8 Since then, several clinical
rials concluded that TKI were more effective than chemother-
py in the treatment of NSCLC patients with EGFR mutation,8,10
xcept when the EGFR mutation is in exon 20 (insertion mutations
nd T790m).11 Current recommendations support EGFR TKI as the
rst-line treatment in patients with advanced NSCLC and EGFR TKI
ensible mutations.12,13
The knowledge of EGFR mutations and its relation with
reatment outcomes was one of the most recent important
teps in lung cancer management. Tumor-free progression and
uality of life parameters are better with TKI when compared
o chemotherapy,14,15 but until now, only studies with Afa-
inib proved survival advantage for the exon 19 deletion over
hemotherapy.16 Real life data, outside clinical trials information,
s poor. In our population neither the correlation between specific
linical features and EGFR mutations nor the effect on survival are
ell established.
In the present study, a cohort of NSCLC patients tested for EGFR
utation was characterized and a survival analysis was  conducted.
atients and MethodsPlease cite this article in press as: Aguiar F, et al. Overall Survival Analy
Cancer (NSCLC) Population. Arch Bronconeumol. 2017. http://dx.doi.o
tudy Design and Population Selection
Retrospective study of a cohort of lung cancer patients (n = 285)
ollowed in Centro Hospitalar São João with stage IIIB/IV NSCLC orPAR.  Publicado  por  Elsevier  España,  S.L.U.  Todos  los  derechos  reservados.
with recurrence or progression at the time of the inclusion period,
who were submitted to EGFR mutation screening, between October
2009 and June 2013. Criteria for screening were adenocarcinoma
histology, specific characteristics as female sex, younger age or
absence of smoking habits. Follow up for survival was  censured
in January 2016.
Study ethical approval was obtained by the Ethical Committee
from the present Hospital.
Data
Age at diagnosis, sex, smoking habits, tumor stage, histopath-
ology, EGFR mutational status, treatments, overall survival and
tumor progression were evaluated.
Tumor staging was based on the 6th TNM system in patients
diagnosed until the end of 2010 and on the 7th TNM system from
2011 to June 2013. The stage considered was  the tumor stage at
diagnose. Regarding smoking habits, patients were classified as
non-smokers, active smokers and ex-smokers (≥6 months of ces-
sation). The overall survival was  calculated using the difference
between the date of death and the diagnosis date.
EGFR Mutation Screening
The EGFR mutation screening was  performed by IPATIMUP
(Institute of Molecular Pathology and Immunology of the University
of Porto). The search of the exons 18–21 of the EGFR gene was  per-
formed through direct sequencing of Polymerase Chain Reaction
(PCR) products obtained from the tumoral cells.
Statistical Analysis
Descriptive statistics (frequency, median and mean) were used
to calculate the demographic and clinical characteristics. Categor-
ical comparisons were calculated by chi-square test or by Fisher’s
exact test. Continuous variables were compared using the t-test.
The survival related results were obtained using the log-rank
Kaplan–Meier product-limit estimates. Patients with one month
or less of overall survival were excluded for the survival analysis.
Statistical significance was set at P < .05 for all analyses. All analyses
were performed using the software IBM SPSS (Statistical Package
for the Social Sciences) v.21.
Results
Demographic characteristics, clinical staging and histology are
summarized in Table 1. Among the 285 patients included, 186sis and Characterization of an EGFR Mutated Non-Small Cell Lung
rg/10.1016/j.arbres.2017.07.012
(65.3%) were male and 99 (34.7%) female. The mean age at diag-
nosis was  66.3 years (standard deviation 11.7 years). The majority
of the patients had some degree of smoke exposure, 88 (30.9%)
were smokers, 84 (29.3%) ex-smokers and 94 (33.0%) never smoked.
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Table  1




patients (n = 54;
18.9%)
EGFR non-mutated
patients (n = 231;
81.1%)
P value
Age at the diagnose – mean (years)/standard deviation 66.31 +/− 11.679 67.41 +/− 11.908 66.06 +/− 11.636 .445a
Gender, no. (%)
Male 186 (65.3%) 17 (31.5%) 169 (73.2%)
Female  99 (34.7%) 37 (68.5%) 62 (21.8%) <.0001b
Smoke habits, no. (%)
Non-smokers 94 (33.0%) 34 (69.4%) 60 (27.6%)
Smokers 88 (30.9%) 5 (10.2%) 83 (38.2%) <.0001b
Ex-smokers [1;2 years] 4 (1.4%) 1 (2.0%) 3 (1.4%)
Ex-smokers [2;5 years] 25 (8.8%) 1 (2.0%) 24 (9.0%)
Ex-smokers [5;10 years] 16 (5.6%) 1 (2.0%) 15 (6.9%)
Ex-smokers [>10 years] 39 (13.7%) 7 (2.0%) 32 (14.7%)
Missing values 19 5 14
ECOG  PS, no. (%)
0 125 (43.9%) 21 (41.2%) 104 (49.3%)
1  81 (28.4%) 10 (19.6%) 71 (33.6%) <.0001b
2 40 (14%) 19 (37.3%) 21 (10.0%)
3  12 (4.2%) 0 (0.0%) 12 (5.7%)
4  4 (1.4%) 1 (2.0%) 3 (1.4%)
Mean/standard deviation 0.81 +/− 0.959 1.02 +/− 0.990 0.76 +/− 0.947
Missing values 23 3 20
Lung  co-morbidities, no. (%)
Without lung co-morbidities 203 (76%) 43 (82.7%) 164 (76.3%)
DPOC  26 (9.1%) 4 (7.7%) 23 (10.7%) .22b
Tuberculosis scars 11 (3.9%) 0 (0.0%) 11 (5.1%)
Others 22 5 17
Missing values 18 2 16
Tumoral staging, no. (%)
IV 211 (74.0%) 41 (75.9%) 170 (73.6%)
IIIB  39 (13.7%) 2 (3.7%) 37 (16.0%)
IIIA  17 (6.0%) 5 (9.3%) 12 (5.2%)
IIB  6 (2.1%) 0 (0.0%) 6 (2.6%)
IIA  3 (1.1%) 1 (1.9%) 2 (0.9%)
IB  1 (0.4%) 1 (1.9%) 0 (0.0%)
IA  8 (2.8%) 4 (7.4%) 4 (1.7%)
.003b
Metastization (IV stage), no. (%)
Local 122 25 97
Pleural effusion 42 (19.9%) 6 (14.6%) 36 (21.2%) .471b
Lung metastasis 62 (29.4%) 15 (36.6%) 59 (34.7%)
Pleural effusion and lung metastasis 14 (6.6%) 4 (9.8%) 10 (5.9%) .482b
Others 4 0 4
Distant 135 26 109
Bone  metastasis 56 (26.5%) 12 (29.3%) 42 (24.7%)
Brain  metastasis 23 (10.9%) 4 (9.8%) 20 (11.8%)
Adrenal metastasis 12 (5.7%) 0 (0.0%) 12 (7.1%)
Hepatic metastasis 11 (5.2%) 2 (4.9%) 9 (5.3%)
Others/multiple metastasis 33 8 26
Histology, no. (%)
Adenocarcinoma 222 (77.9%) 51 (94.4%) 171 (74.0%)
Squamous-cell carcinoma 32 (11.2%) 0 (0.0%) 32 (13.9%) .063b
NOS 30 (10.5%) 3 (5.6%) 27 (11.7%)
Neuroendocrine tumor 1 (0.4%) 0 (0.0%) 1 (0.4%)
Sarcomatoide carcinoma 1 (0.4%) 0 (0.0%) 1 (0.4%)










b Results from Chi-Square calculation, unless the cases where less of five patients
ithin ex-smokers, most (n = 39; 46.4%) quit smoking over the last
en years before diagnosis.
Regarding clinical staging, most patients (n = 250; 87.7%) werePlease cite this article in press as: Aguiar F, et al. Overall Survival Analy
Cancer (NSCLC) Population. Arch Bronconeumol. 2017. http://dx.doi.o
iagnosed at advanced stages of the disease and 35 (12.3%) pre-
ented with non-advanced stages with progression at the time of
GFR analysis.e expected for each group, when Fisher Exact test was  used.
Among stage IV patients, 72 (34.1%) had intrapulmonary
metastasis, 85 (40.3%) distant metastasis and 50 (23.7%) both
intrapulmonary and distant metastasis. The most frequent organssis and Characterization of an EGFR Mutated Non-Small Cell Lung
rg/10.1016/j.arbres.2017.07.012
metastasized were bone (n = 56; 26.5%), followed by brain (n = 23;
10.9%), adrenal (n = 12; 5.7%) and liver (n = 11; 5.2%). Twenty-seven
patients (12.8%) had more than one organ involved.
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ig. 1. Types of treatments of the 250 patients with advanced disease. EGFR – epide
nhibitor; BSC – best supportive care.
From the analysis of 285 lung tissue samples, 222 (77.9%)
orresponded to adenocarcinoma, 32 (11.2%) to squamous cell car-
inoma and 30 (10.5%) to not otherwise specified (NOS) NSCLC.
here were sporadic samples (n = 2, 0.8%) of neuroendocrine and
arcomatoid tumors.
The EGFR screening was made on samples obtained from
ransthoracic biopsies in 88 (30.9%) cases, bronchial biopsies in 84
29.5%), surgical specimens in 29 (10.2%), pleural fluid in 26 (8.4%)Please cite this article in press as: Aguiar F, et al. Overall Survival Analy
Cancer (NSCLC) Population. Arch Bronconeumol. 2017. http://dx.doi.o
nd biopsies of metastasis in 18 (6.3%).
EGFR mutations were detected in 54 patients (18.9%), of
hich 25 (46.3%) were in exon 19, 20 (37.0%) in exon 21,
 (9.3%) in exon 20, and 4 (7.4%) in exon 18 (Table 2).growth factor receptor; WT – wild type; CT – chemotherapy; TKI – tyrosine-kinase
There were no samples with more than one mutation. The
most common mutations were in-frame deletions at exon 19
(n = 25; 46.3%) ant the p.L858R missense mutation in exon 21
(n = 20; 37.1%).
In the EGFR mutated group there was a predominance of female
versus male (P < .001) and of non-smokers versus smokers or ex-
smokers (P < .001).
There was  no statistically significant difference between groupssis and Characterization of an EGFR Mutated Non-Small Cell Lung
rg/10.1016/j.arbres.2017.07.012
regarding tumor progression. The most frequent de novo metasta-
sis diagnosed in both groups were bone metastasis (n = 33; 37.5%)
followed by brain metastasis (n = 27; 30.7%) and hepatic metastasis
(n = 20; 22.7%).
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Table  2
EGFR Mutations.
Exon n % n (%) Total
18
c.2156G > C (G719A) 2 50.0 4 (7.41%)
c.2117T > C 1 25.0
c.2156G > A 1 25.0
19
c.2235 2249del15 11 44 25 (46.30%)
c.2236 2250del15 5 20
c.2240 2257del18 3 12
c.2237 2254del19insT 2 8
c.2236 2252del17insAT 1 4
c.2240 2248del9 1 4
c.2240 2254del15 1 4
2239 2248del10insC 1 4
20
c.2312 2313ins9 2 40 5 (9.26%)
c2307 2308ins6 1 20
c.2308 2309ins9 1 20
c.2308ins9 1 20
21














































ig. 2. Kaplan–Meier survival curve of EGFR mutated patients (continuous line)
ersus EGFR non-mutated patients (dotted line). P value = .007.
The first line treatment options, within the 43 EGFR mutated
atients with advanced disease (79.6% of all EGFR mutant cases),
ere TKI in 31 (72.1%) patients, chemotherapy in 10 (23.3%)
atients and best supportive care in 2 (4.7%) patients.
Regarding the TKI treatment, 37 (86.0%) EGFR mutant patients
ere exposed to TKI: 31 (83.8%) in first line of treatment, 4 (10.8%)
n second line and 2 (5.4%) in third line (Fig. 1). The TKI more
ften used was Erlotinib in 21 (65.8%) patients and Gefitinib in
0 (27.0%). The mean duration of the TKI treatment was 8.8 ± 7.7
onths (median of 8 months).
The global median overall survival (OS) was 12.0 months [95%
onfidence interval (CI) 9.6–14.4]. Analyzing the cohort by its EGFR
utational status, the median overall survival of the non-mutated
roup was 11.0 months (95% CI 9.1–12.9) and 20.0 months for the
utated group (95% CI 10.1–29.9) (P = .007) (Fig. 2).
In the non-mutated group, younger patients (<65 years; P < .001)
nd female sex (P = .03) had better overall survival (Table 3). Among
he EGFR mutated group, sex (P = .342), age (P = .253), smokingPlease cite this article in press as: Aguiar F, et al. Overall Survival Analy
Cancer (NSCLC) Population. Arch Bronconeumol. 2017. http://dx.doi.o
abits (P = .666) and the EGFR exon mutated [KM comparison of
 exons: P = .188, KM of TKI sensible mutations versus TKI non-
ensible mutations (EGFR exon 20 insertion mutations): P = .362]
id not have a statistical impact on OS. PRESS
ol. 2017;xxx(xx):xxx–xxx 5
Tumor staging <IIIB at diagnosis was related to better OS  in both
mutated (P = .005) and non-mutated (P < .001) populations.
The two-year overall survival of global population was 26.7%,
corresponding to 75 patients (26.7%), 52 (20.6%) non-mutated
patients and 23(42.6%) EGFR mutated. At the end of follow-up (Jan-
uary 2016), 32 (11.2%) patients were alive [12 (22.2%) EGFR mutated
and 20 (8.7%) non-mutated patients].
Discussion
To our best knowledge, this is one of the first overall survival
analysis, outside of clinical trials, comparing EGFR mutated patients
to EGFR non-mutated patients with lung cancer. Our results showed
a frequency of EGFR mutation of 18.9% and better overall survival
in this population.
The mutation distribution was predominantly in the exons 19
and 21 [25 (46.3%) and 20 (37.0%) mutations, respectively], total-
izing 45 (83.3%) of all mutations. 5 (9.3%) mutations occurred in
exons 20 and 4 (7.4%) in exon 18. This distribution is similar to
other studies.17,18
The frequency of EGFR mutations varies geographically. Higher
frequencies are found in Asia, as shown in the work of Shi et al.
(51.4%) that represents several regions of that continent.19 In the
Latin America intermediate frequencies are 33.2% in Argentina,
Colombia, Mexico and Peru.20 In the European region, stud-
ies revealed a frequency of 16.6%, 12.3% and 4.9% in Spain,10
Denmark21 and Germany.22
The frequency of EGFR mutations in the Portuguese population
is undetermined. In the study of Mello et al., the frequency of this
mutation was 16.9%17 while in Castro et al. the global frequency
was 13.1%.23 Still, in this last work, different frequencies were
determined: 16.3% and 10.4% corresponding to different inclusion
criteria, from 2006 to 2009 were included patients with adeno-
carcinoma or without smoking habits, while in 2010 all patients
with NSCLC were included.23 Our mutation frequency of 18.9% is
slightly higher to those published. Some bias related to phenotypic
preselection could have occurred. The majority were stage III/IV
adenocarcinoma but some patients were selected based on their
characteristics such as non-smokers, female sex, younger age and
progression or recurrence of tumor staged <IIIB, independently of
their histology. EGFR mutations were only identified in adenocar-
cinoma and NOS samples, reinforcing the histologic type as criteria
to the EGFR screening. EGFR mutation frequency vary along studies
not only due to ethnical particularities but also to methodological
discrepancies, being lower when restrictive clinical criteria were
not used. To clarify this issue it is needed an epidemiologic study.
Association between EGFR mutation status and survival is diffi-
cult to estimate, particularly outside of a clinical trial setting. The
obstacle to this association could be explained by the different lines
of treatment and the crossover of treatments.24,25 The median OS
of the EGFR mutated group was  9 months superior to the OS of the
non-mutated group (20.0 vs 11.0 months; P = .007). This values for
OS are similar to other clinical trials,16,24,26–28 particularly in the
EURTAC trial. These OS difference could be explained by a possi-
ble influence of the mutational status in the prognosis and by the
use of more efficacious drugs than the usual chemotherapy in the
mutated population.
Some studies, as in the Iressa Pan-Asia Survival Study (IPASS),
comparing gefitinib with paclitaxel plus carboplatin as the first-
line therapy in Asian patients, have demonstrated a statistically
significant higher response rate to chemotherapy in EGFR mutatedsis and Characterization of an EGFR Mutated Non-Small Cell Lung
rg/10.1016/j.arbres.2017.07.012
patients (47.3% versus 23.5%) than patient without EGFR muta-
tions, but the progression-free survival (PFS) and OS were not
different between patients with and without EGFR mutation in













































































































Kaplan–Meier Global Survival Analysis.
Total population (n = 254;100%) EGFR Non-mutated population (n = 204; 80.3%) EGFR mutated population (n = 50; 19.7)
n Mediana CI 95%a Standard
deviationa
P n Mediana CI 95%a Standard
deviationa




<65  years 113 17 13.53 – 20.47 1.77 <65 years 93 17 12.28 – 21.73 2.41 <65 years 20 16 9.43 – 22.57 3.35
>=65  years 141 11 8.95 – 13.05 1.05 >=65 years 111 10 7.95 – 12.06 1.05 >=65 years 30 24 9.24 – 38.76 7.53
.031  .001 .282
Gender  Gender Gender
Female  91 16 10.22 – 13.78 0.91 Female 56 16 9.72 – 22.28 0.87 Female 35 16 11.38 – 20.62 8.54
Male  163 12 12.41 – 19.59 1.83 Male 148 10 8.30 – 11.70 3.21 Male 15 35 18.26 – 51.74 2.36
.038 .035 .211
Smoke habits Smoke habits Smoke habits
Non  smoker 85 16 10.58 – 21.42 2.77 Non smoker 53 17 7.84 – 26.16 4.67 Non smoker 32 16 8.25 – 23.75 3.95
Smoker  80 10 8.47 – 11.53 0.78 Smoker 76 9 7.49 – 10.51 0.77 Smoker 4 20 10.20 – 29.80 5.00
Ex-smoker 76 12 10.03 – 13.97 10.03 Ex-smoker 66 12 10.56 – 13.45 0.74 Ex-smoker 10 25 0.00 – 57.54 16.60
.487 .771 .666
Tumoral stage Tumoral stage Tumoral stage
<IIIB  32 49 <IIIB 21 49 <IIIB 11
≥IIIB 207 10 8.06 – 11.94 0.99 ≥IIIB 169 10 8.60 −0.13711.41 0.72 ≥IIIB 38 15 7.96 – 22.04 3.91
<.001  <.001 .008
Distant  metastasis Distant metastasis Distant metastasis
0  143 19 15.09 – 22.90 1.99 0 115 18 13.96 – 22.04 2.06 0 28 29 6.96 – 51.04 11.24
1  88 8 6.38 – 9.62 0.83 1 72 8 7.18 – 8.82 0.42 1 16 20 8.24 – 3.76 6.00
>1  19 6 4.31 – 7.69 0.86 >1 13 5 3.59 – 6.41 0.72 >1 6 7 0.00 – 20.20 6.74
<.001  <.001 .007
Mutational  status
EGFR mutated 204 20 27.20 – 52.47 5.05
EGFR wildtype 50 11 17.20 – 23.56 0.99
.007
EGFR mutated exonb
18 4 20 6.28 – 33.72 7.00
19 24 31 15.40 – 46.60 7.96
20 4 2
21 18 14 3.61 – 29.90 5.30
.188
18  + 19 + 21 exons 46 21 8.81 – 33.19 6.22
20 exon insentions 4 2
.362
a Values in months.
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utated patients was significantly longer than those without EGFR
utations in groups of patients who received chemotherapy alone
ithout gefitinib or erlotinib.29,30 The study of Lin CC et al.31 cor-
oborated that EGFR mutations are associated with a higher tumor
esponse rate to chemotherapy, but are not a predictive biomarker
or PFS and OS. Applying the Kaplan–Meier product-limit estimates
Table 3) in the global population, the factors that were associated
ith a better OS were age inferior to 65 years, female sex, tumor
tage <IIIB and the presence of EGFR mutation.
In the non-mutated population features like age <65 years,
emale sex and stage <IIIB were related to better OS. Among the
GFR mutated patients gender, age and the mutated exon did
ot influence the prognosis, reinforcing that the presence of EGFR
utations is a major factor associated to better OS.
Results regarding clinical factors that may  influence progno-
is also vary across studies. Some authors report an association
etween extrathoracic metastasis, in particular brain metastasis,
nd the presence of L858 mutation with worse survival.32–34
In this study the relevance of the molecular study was con-
rmed, permitting the identification of the EGFR mutated patients
ho have a distinct clinical behavior regarding overall survival and
esponse to TKI.
The decision to screen for EGFR mutation was  influenced by
denocarcinoma histology, female gender and non-smoking sta-
us. This selection bias represents a major limitation of the present
tudy. Within the EGFR mutated group there were only a small
roup of patients with non-sensible TKI mutations (n = 5). For over-
ll survival calculations, the small size of this group did not permit
ny conclusion in particular. Those patients were considered within
he rest of the EGFR mutated patients which could represent a lim-
tation for the study results. The study reflects the clinical results
nd therefore has inherent limitations such its retrospective char-
cter and a small population analyzed, but its strength is that it is
ne of the first real life studies aiming the OS of an EGFR mutated
opulation.
Our data showed a better overall survival for EGFR activating
utated patients independently of the clinical characteristics, sug-
esting that it can be a favorable prognostic marker.
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